

Chronic Wasting Disease and Atypical forms of BSE and scrapie are not transmissible to mice expressing wild-type levels of human PrP

Running title: CWD and Atypical TSE Transmission to HuTg mice

Rona Wilson¹, Chris Plinston¹, Nora Hunter¹, Cristina Casalone², Cristiano Corona², Fabrizio Tagliavini³, Silvia Suardi³, Margherita Ruggerone³, Fabio Moda³, Silvia Graziano⁴, Marco Sbriccoli⁴, Franco Cardone⁴, Maurizio Pocchiari⁴, Loredana Ingrosso⁴, Thierry Baron⁵, Juergen Richt⁶‡, Olivier Andreoletti⁷, Marion Simmons⁸, Richard Lockey⁸, Jean C. Manson¹, and Rona M Barron^{1*}

¹Neuropathogenesis Division, The Roslin Institute and R(D)SVS, University of Edinburgh, Roslin, Midlothian, UK

²Istituto Zooprofilattico Sperimentale del Piemonte, Liguria e Valle d'Aosta, Turin, Italy

³IRCCS Foundation, "Carlo Besta" Neurological Institute, Milan, Italy

⁴Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy

⁵Agence Nationale de Sécurité Sanitaire, Lyon, France

⁶USDA, ARS, National Animal Disease Center, PO Box 70, Ames, IA 50010, USA

⁷UMR 1225 Interactions Hôtes-Agents Pathogènes, INRA, Ecole Nationale Vétérinaire, 23 chemin des Capelles, B.P. 87614, 31076 Toulouse Cedex 3, France

⁸Neuropathology Section, Department of Pathology and Host Susceptibility, Animal Health and Veterinary Laboratories Agency, Addlestone, Surrey, KT15 3NB, UK

‡ Current affiliation: Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, United States of America

*Corresponding Author

Neuropathogenesis Division
The Roslin Institute and R(D)SVS, University of Edinburgh
Roslin
Midlothian, EH25 9PS
UK
Tel 0131 527 4200
Fax 0131 440 0434
rona.barron@roslin.ed.ac.uk

Contents Category: TSE Agents

Word count summary: 139

Word count main text: 2315

Number of tables and figures: 2

Chronic Wasting Disease and Atypical forms of BSE and scrapie are not transmissible to mice expressing wild-type levels of human PrP

Summary

The association between bovine spongiform encephalopathy (BSE) and variant Creutzfeldt-Jakob disease (vCJD) has demonstrated that cattle TSEs can pose a risk to human health and raises the possibility that other ruminant TSEs may be transmissible to humans. In recent years, several new TSEs in sheep, cattle and deer have been described and the risk posed to humans by these agents is currently unknown. In this study, we inoculated two forms of atypical BSE (BASE and H-type BSE), a chronic wasting disease (CWD) isolate, and seven isolates of atypical scrapie into gene-targeted transgenic (Tg) mice expressing the human prion protein (PrP). Upon challenge with these ruminant TSEs, gene-targeted Tg mice expressing human PrP did not show any signs of disease pathology. These data strongly suggest the presence of a substantial transmission barrier between these recently identified ruminant TSEs and humans.

Main Text

Transmissible spongiform encephalopathies (TSEs) or prion diseases are a group of fatal infectious neurodegenerative diseases that include scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle, chronic wasting disease (CWD) in cervids, and Creutzfeldt-Jakob disease (CJD) in humans. TSEs are characterised by the accumulation in the brain of PrP^{TSE}, which is a protease resistant conformational variant of the normal host encoded cellular prion protein (PrP^C). Due to the infectious nature of TSEs, these diseases can be transmitted via a number of different routes. While TSEs tend to transmit more readily within species they are also able to transmit between species, although efficiency is dependent on both the TSE agent and host. Often transmission to a new species may initially present low transmission rates, however further passage within the new species may result in increased transmission rates and shorter incubation periods. The transmission of BSE to humans through contaminated food is thought to be the cause of the variant form of Creutzfeldt-Jakob disease (vCJD) (Bruce *et al.*, 1997; Hill *et al.*, 1997). This relationship reveals a potential risk of transmission of other ruminant TSEs to humans. In the present study we aimed to assess this risk by using gene-targeted Tg mice expressing human PrP as a model system for investigating transmissibility of several atypical ruminant TSE agents (atypical BSE, atypical scrapie and CWD).

Until recently, TSE disease in cattle was believed to be caused by a single TSE strain, classical BSE (BSE-C). However, two atypical BSE agents have recently been reported (Biacabe *et al.*, 2004; Casalone *et al.*, 2004; Jacobs *et al.*, 2007; Stack *et al.*, 2009), and are identified as H-type BSE (BSE-H) and bovine amyloidotic spongiform encephalopathy (BASE, also named BSE-L). Given the association of classical BSE with vCJD, in the present study we investigated the potential risk of transmission of these atypical forms of BSE to humans. CWD is a fatal, endemic TSE disease affecting free-ranging and captive cervids, including mule deer, white-tailed deer, Rocky Mountain elk and moose. Although CWD has not been reported in Europe, cases have been found in 14 USA states, two Canadian provinces and in South Korea. CWD has been shown to spread via a variety of routes (Denkers *et al.*, 2010;

Mathiason *et al.*, 2009; Miller & Williams, 2003; Miller *et al.*, 1998; Sigurdson *et al.*, 1999; Trifilo *et al.*, 2007), and transmission between cervids is highly efficient. In addition to brain, spinal cord and lymphoid tissues (Race *et al.*, 2007; Sigurdson *et al.*, 1999; Spraker *et al.*, 2002), PrP^{TSE} has also been found in muscle, saliva, urine, fat, blood and antler velvet of CWD-infected cervids (Angers *et al.*, 2006; Angers *et al.*, 2009; Haley *et al.*, 2009; Haley *et al.*, 2011; Mathiason *et al.*, 2006; Race *et al.*, 2009a). Due to hunting of deer and elk, the possible consumption of CWD-infected meat raises concern over the risk to humans. Furthermore, previous studies have shown the intracerebral and oral transmission of CWD into squirrel monkeys (Race *et al.*, 2009b). Atypical scrapie, also known as Nor98, was first identified in 1998 in sheep in Norway (Benestad *et al.*, 2003) and can be distinguished from classical scrapie and BSE by the biochemical features of PrP^{TSE}, and its pathology and transmission characteristics. Despite the fact that no evidence of transmissibility of classical scrapie to humans has ever been obtained, atypical scrapie is a newly identified TSE, and is now known to have been present throughout the BSE epidemic (Benestad *et al.*, 2008; Benestad *et al.*, 2003) thus the risk to humans warrants investigation.

To address the transmissibility of these recently recognized ruminant TSEs to humans, we performed inoculations of two forms of atypical BSE (BASE and H-type), one isolate of CWD (from white-tailed deer), six field isolates of atypical scrapie, and one sheep passaged isolate of atypical scrapie into a panel of gene-targeted Tg mice expressing human PrP under the same spatial and temporal controls as wild-type PrP (Bishop *et al.*, 2006). Previously, three lines of Tg mice (HuMM, HuMV and HuVV) were generated (Bishop *et al.*, 2006) which represent the genetic diversity in the human population, due to the PrP codon 129-methionine/valine polymorphism. Interestingly, this polymorphism correlates with human susceptibility to TSE, and all confirmed clinical cases of vCJD to date have occurred in individuals who are methionine homozygous at PrP codon 129. In addition we also inoculated these ruminant TSEs into gene-targeted Tg mice expressing bovine PrP (named Bov6 mice) and wildtype 129/Ola mice (which have the same genetic background as the human and bovine PrP Tg mice) as controls.

For experimental setup at The Roslin Institute, groups (n=24) of gene-targeted Tg mice expressing human (HuMM, HuMV and HuVV) or bovine PrP (Bov6) and 129/Ola controls were inoculated intracerebrally (i.c.) with 0.02 ml of 10⁻¹ brain homogenate (BASE, BSE-H, CWD or atypical scrapie) into the right cerebral hemisphere under halothane anaesthesia. As inocula were sourced from field cases they were treated with gentamycin (0.25mg/ml) prior to inoculation to remove bacterial contamination. In complementary studies, groups of the same HuMM, HuMV and HuVV mice were also inoculated i.c. (20µl) and i.p.(100 µl) with BASE inoculum at “Carlo Besta” Neurological Institute, Milan, and i.c (20µl) with two different cases of BASE and BSE at the Istituto Superiore di Sanità, Rome, Italy. Mice were scored each week for clinical signs of disease and killed by cervical dislocation or carbon dioxide (Rome, Italy) at a pre-defined clinical endpoint, or due to welfare reasons (Dickinson *et al.*, 1968). Brains and spleens were recovered at post mortem. To assess the abundance and location of TSE-associated vacuolation in grey and white matter of the brain, sections were cut (6µm) from each mouse brain and stained using haematoxylin and eosin (H&E). TSE-related vacuolation was assessed at nine grey-matter regions (medulla, cerebellum, superior colliculus, hypothalamus,

thalamus, hippocampus, septum, retrosplinal cortex, cingulated and motor cortex) and three regions of white matter (cerebellar white matter, midbrain white matter, and cerebral peduncle) as previously described (Fraser & Dickinson, 1967). Sections of brain tissue were also examined for abnormal PrP deposition, which is a key pathological marker of TSE infection, by immunohistochemistry and western blot analysis following PTA precipitation using MAb6H4 (Prionics) as described previously (Bishop *et al.*, 2006). Although some mice in these experiments exhibited clinical signs of disease, following analysis of all mice in this study for vacuolar pathology and PrP deposition, no signs of TSE pathology were detected in any of the gene-targeted human PrP Tg mice (Table 1). Transmission of BASE and BSE-H in Bov6 and 129/Ola mice was detected as previously described (Wilson *et al.*, 2012), however no transmission of atypical scrapie was observed in these two control mouse lines.

Recent studies of TSE inoculations in mice that result in inefficient disease transmission have identified that lymphoid tissues were more permissive to TSEs than brain (Béringue *et al.*, 2012). Tg338 (ovine PrP) mice inoculated with CWD and Tg650 (human PrP) mice inoculated with cattle BSE did not develop high rates of clinical disease or significant PrP^{TSE} in brain, but a large proportion of inoculated mice had PrP^{TSE} detectable in spleen. 60 mice inoculated at Roslin with the atypical TSE agents (either showing clinical signs or a selection of the oldest mice, ranging from 321dpi to 730dpi), were analysed for the presence of peripheral agent replication using the IDEXX HerdChek Bovine Spongiform Encephalopathy (BSE) Antigen Test Kit, which is an antigen capture enzyme immunoassay (EIA) used to detect aggregated PrP in post-mortem tissues. Spleens derived from human PrP Tg mice challenged with BASE, BSE-H, CWD and atypical scrapie were homogenised in sterile saline in a Rybolyser (Hybaid, Middlesex, UK) to achieve a 30% homogenate and processed in the IDEXX HerdChek assay. All assay readouts were negative for the presence of disease related PrP. Hence there was no evidence of increased cross-species transmission in lymphoid tissues of gene-targeted human Tg mice inoculated with these atypical TSE agents.

Interestingly several human PrP Tg mice were scored as showing positive clinical signs of disease despite the lack of disease associated pathology, most notably in those mice inoculated with atypical scrapie (Table 2). Indeed, out of a total of 662 mice inoculated with six atypical scrapie field isolates, 25 had clinical signs of TSE (10 x HuMM, 9 x HuMV, 4 x HuVV, 1 x Bov6, 1 x 129/Ola). If the data were simply due to scoring errors we would expect similar numbers of cases in all groups. However, on the assumption that mice responded and were scored independently of one another (i.e., all mice had an equal chance of being scored as showing clinical signs) the distribution of clinical cases between the 30 groups of atypical scrapie inoculated Tg mice is statistically significant at $p \leq 0.003$. The relevance of this observation is unclear. It is possible that the clinical signs observed in these mice are due to non-TSE intercurrent illnesses encountered because of the extended nature of these transmission experiments. However scoring protocols are robust and do not usually yield high numbers of false negative results when compared with disease pathology post mortem. It is possible that these clinical signs indicate a different TSE disease phenotype whereby the pathological signs associated with disease cannot be detected using our conventional methods of tissue analysis. This hypothesis is being further investigated by subpassage from selected cases to identify any evidence of

subclinical disease or low level agent replication. While control ovine Tg mice were not available to include in the original transmission panel at The Roslin Institute, 5/6 of the atypical scrapie field isolates were inoculated into Tg338 ovine transgenic mice at AHVLA (Griffiths *et al.*, 2010) (sample numbers 2 and 5 in Griffiths *et al.*, and Spiropoulos-personal communication). All five isolates transmitted efficiently to Tg338 transgenic mice (incubation times ~200 days post inoculation), proving the infectivity of the source material.

Our results indicate that BASE, H-type BSE, CWD and atypical scrapie do not transmit to gene-targeted Tg mice expressing wild type levels of human PrP, however subpassage experiments are currently in progress to assay for any possible subclinical infection in mice that received these agents. The lack of BASE transmission to HuMM Tg mice has been confirmed following independent transmissions to mice in three different laboratories (Roslin Institute, “Carlo Besta” Neurological Institute, Istituto Superiore di Sanita). Surprisingly, other studies have shown the transmission of BASE into microinjection-derived human PrP Tg mice (Tg40) (Kong *et al.*, 2008), which were reported to also express human PrP-129M at wildtype levels. Despite the apparent similarities in expression levels between these lines, previous studies have produced other conflicting results between the Tg40 line and our targeted HuMM Tg line. While Tg40 mice were reported to be highly susceptible to sCJD(MM2) (Kong *et al.*, 2008), HuMM mice inoculated with sCJD(MM2) showed no clinical signs of disease (Bishop *et al.*, 2010). The reasons for this discrepancy are not clear, but may be due to different mouse genetic background, or a more subtle difference in PrP expression levels in each Tg line. Other studies have shown the transmission of BASE into overexpressing human PrP Tg mice (Tg 650; ~6 fold overexpression), with prolonged incubation times of 600-700 days. However similarly to our findings they did not achieve transmission of H-type BSE into Tg650 mice (Beringue *et al.*, 2008). Previous studies have shown CWD TSEs do not transmit to mice overexpressing human PrP (Sandberg *et al.*, 2010; Tamguney *et al.*, 2006). Furthermore, other studies investigating transmissibility of elk CWD TSEs, did not observe transmission into Tg40 mice (human PrP Tg) (Kong *et al.*, 2005). Studies have shown levels of PrP^{TSE} in lymphoid tissues are much higher in CWD-infected deer compared to elk (Race *et al.*, 2007), suggesting deer may be more likely to transmit disease to other cervids and noncervids. In the present study we challenged our human PrP Tg mice with CWD-infected white-tailed deer, but did not observe any signs of disease. However it may be possible that CWD can be caused by multiple strains (Angers *et al.*, 2010) and as distinct cervid TSE strains become recognised and characterised, further studies will be required to assess human risk.

In this study, we examined, for the first time, the transmissibility of BASE, BSE-H, CWD and atypical scrapie into gene-targeted Tg mice expressing human PrP and show that these mice are highly resistant to infection with these animal TSEs. In contrast to recently published research (Béringue *et al.*, 2012), we did not find any evidence of disease within lymphoid tissue of gene-targeted HuTg mice inoculated with these atypical TSE agents. While other studies have conducted similar experiments using overexpressing human PrP Tg mouse lines, the Tg mice used in this study are produced by gene replacement and do not suffer from any adverse phenotypes which can be associated with overexpression or ectopic expression of the transgene in standard Tg lines. While overexpression may increase sensitivity of these models by reducing incubation times, these levels of expression do not occur in host

species. Gene-targeted models may therefore more closely represent infection and disease progression in nature. Indeed, previous studies have shown transmission of sporadic CJD, vCJD and sheep BSE into gene-targeted human PrP Tg mice, demonstrating that these mice do live long enough to show signs of infection, supporting the use of targeted mouse models to analyse TSE disease transmission (Bishop *et al.*, 2010; Bishop *et al.*, 2006; Plinston *et al.*, 2011). In conclusion, the results presented here strongly suggest the presence of a significant transmission barrier between these ruminant TSEs and humans. However, while TSEs are still present in the environment, the potential for cross-species transmission and emergence of new TSE isolates remains, thus supporting the need for continued surveillance of these agents.

Acknowledgements

The authors would like to acknowledge I. McConnell, V. Thomson, S. Cumming, S. Carpenter, R. Greenan, K. Hogan, I. Itró, E. Laconi, M. Venditti, A. Valanzano, M. Bonanno, and N. Bellizzi for experimental setup, care and scoring of the animals; A. Coghill, A. Boyle, S. Mack and G. McGregor for histology processing and scoring; I. Martino, D. Biondo, and A. De Pascalis for western blotting. We thank the Wisconsin Department of Natural Resources for the CWD brain sample. All mouse experiments were reviewed and approved by the Local Ethical Review Committee and performed under licence from the United Kingdom Home Office in accordance with the United Kingdom Animals (Scientific Procedures) Act 1986 and by the Service for Biotechnology and Animal Welfare of the Istituto Superiore di Sanità, authorized by the Italian Ministry of Health according to Legislative Decree 116/12 which has implemented in Italy the European Directive 86/609/EEC on laboratory animals protection. This work was funded by contract M03054 from the Food Standards Agency (FSA), UK; contract SE1441 from the Department for Environment, Food and Rural Affairs (Defra); contract 2004–506579 “NeuroPrion” from the European Union, and from the Italian Ministry of Health; and contract NIAID PO1 AI077774-01 “Pathogenesis, Transmission and Detection of Zoonotic Prion Diseases”. The authors declare that this study was carried out under the following Research Project funded by the Italian Ministry of Health: Ricerca Finalizzata 2009 - 09F01 “The novel emergence of atypical animal and human TSEs. A clinical, pathological, molecular, and experimental approach to define interspecies similarities and strain connections”

References

- Angers, R. C., Browning, S. R., Seward, T. S., Sigurdson, C. J., Miller, M. W., Hoover, E. A. & Telling, G. C. (2006). Prions in skeletal muscles of deer with chronic wasting disease. *Science* **311**, 1117.
- Angers, R. C., Seward, T. S., Napier, D., Green, M., Hoover, E., Spraker, T., O'Rourke, K., Balachandran, A. & Telling, G. C. (2009). Chronic wasting disease prions in elk antler velvet. *Emerg Infect Dis* **15**, 696-703.
- Angers, R. C., Kang, H. E., Napier, D., Browning, S., Seward, T., Mathiason, C., Balachandran, A., McKenzie, D., Castilla, J. & other authors (2010). Prion strain mutation determined by prion protein conformational compatibility and primary structure. *Science* **328**, 1154-1158.

301 **Benestad, S., Sarradin, P., Thu, B., Schonheit, J., Tranulis, M. & Bratberg, B.**
302 **(2003).** Cases of scrapie with unusual features in Norway and designation of a new
303 type, Nor98. *Vet Rec* **153**, 202 - 208.

304 **Benestad, S. L., Arsac, J. N., Goldmann, W. & Noremark, M. (2008).**
305 Atypical/Nor98 scrapie: properties of the agent, genetics, and epidemiology. *Vet Res*
306 **39**, 19.

307 **Beringue, V., Herzog, L., Reine, F., Le-Dur, A., Casalone, C., Vilotte, J. L. &**
308 **Laude, H. (2008).** Transmission of atypical bovine prions to mice transgenic for
309 human prion protein. *Emerg Infect Dis* **14**, 1898-1901.

310 **Béringue, V., Herzog, L., Jaumain, E., Reine, F., Sibille, P., Le Dur, A., Vilotte,**
311 **J.-L. & Laude, H. (2012).** Facilitated Cross-Species Transmission of Prions in
312 Extraneural Tissue. *Science* **335**, 472-475.

313 **Biacabe, A. G., Laplanche, J. L., Ryder, S. & Baron, T. (2004).** Distinct molecular
314 phenotypes in bovine prion diseases. *EMBO Rep* **5**, 110-115.

315 **Bishop, M. T., Will, R. G. & Manson, J. C. (2010).** Defining sporadic Creutzfeldt-
316 Jakob disease strains and their transmission properties. *Proc Natl Acad Sci U S A* **107**,
317 12005-12010.

318 **Bishop, M. T., Hart, P., Aitchison, L., Baybutt, H., Plinston, C., Thomson, V.,**
319 **Tuzi, N., Head, M., Ironside, J. & other authors (2006).** Predicting susceptibility
320 and incubation time of human-to-human transmission of vCJD. *Lancet Neurology* **5**,
321 393-398.

322 **Bruce, M. E., Will, R. G., Ironside, J. W., McConnell, I., Drummond, D., Suttie,**
323 **A., McCardle, L., Chree, A., Hope, J. & other authors (1997).** Transmissions to
324 mice indicate that 'new variant' CJD is caused by the BSE agent. *Nature* **389**, 498-
325 501.

326 **Casalone, C., Zanusso, G., Acutis, P., Ferrari, S., Capucci, L., Tagliavini, F.,**
327 **Monaco, S. & Caramelli, M. (2004).** Identification of a second bovine amyloidotic
328 spongiform encephalopathy: molecular similarities with sporadic Creutzfeldt-Jakob
329 disease. *Proc Natl Acad Sci U S A* **101**, 3065-3070.

330 **Denkers, N. D., Seelig, D. M., Telling, G. C. & Hoover, E. A. (2010).** Aerosol and
331 nasal transmission of chronic wasting disease in cervidized mice. *J Gen Virol* **91**,
332 1651-1658.

333 **Dickinson, A. G., Meikle, V. M. & Fraser, H. (1968).** Identification of a gene which
334 controls the incubation period of some strains of scrapie agent in mice. *J Comp Pathol*
335 **78**, 293-299.

336 **Fraser, H. & Dickinson, A. G. (1967).** Distribution of experimentally induced
337 scrapie lesions in the brain. *Nature* **216**, 1310-1311.

338 **Griffiths, P. C., Spiropoulos, J., Lockey, R., Tout, A. C., Jayasena, D., Plater, J.**
339 **M., Chave, A., Green, R. B., Simonini, S. & other authors (2010).** Characterization
340 of atypical scrapie cases from Great Britain in transgenic ovine PrP mice. *J Gen Virol*
341 **91**, 2132-2138.

342 **Haley, N. J., Seelig, D. M., Zabel, M. D., Telling, G. C. & Hoover, E. A. (2009).**
343 Detection of CWD prions in urine and saliva of deer by transgenic mouse bioassay.
344 *PLoS ONE* **4**, e4848.

345 **Haley, N. J., Mathiason, C. K., Carver, S., Zabel, M., Telling, G. C. & Hoover, E.**
346 **A. (2011).** Detection of Chronic Wasting Disease Prions in Salivary, Urinary, and
347 Intestinal Tissues of Deer: Potential Mechanisms of Prion Shedding and
348 Transmission. *J Virol* **85**, 6309-6318.

349 **Hill, A. F., Desbruslais, M., Joiner, S., Sidle, K. C. L., Gowland, I., Collinge, J.,**
350 **Doey, L. J. & Lantos, P. (1997).** The same prion strain causes vCJD and BSE.
351 *Nature* **389**, 448-450.

352 **Jacobs, J. G., Langeveld, J. P., Biacabe, A. G., Acutis, P. L., Polak, M. P.,**
353 **Gavier-Widen, D., Buschmann, A., Caramelli, M., Casalone, C. & other authors**
354 **(2007).** Molecular discrimination of atypical bovine spongiform encephalopathy
355 strains from a geographical region spanning a wide area in Europe. *J Clin Microbiol*
356 **45**, 1821-1829.

357 **Kong, Q., Huang, S., Zou, W., Vanegas, D., Wang, M., Wu, D., Yuan, J., Zheng,**
358 **M., Bai, H. & other authors (2005).** Chronic wasting disease of elk: transmissibility
359 to humans examined by transgenic mouse models. *J Neurosci* **25**, 7944-7949.

360 **Kong, Q., Zheng, M., Casalone, C., Qing, L., Huang, S., Chakraborty, B., Wang,**
361 **P., Chen, F., Cali, I. & other authors (2008).** Evaluation of the human transmission
362 risk of an atypical bovine spongiform encephalopathy prion strain. *J Virol* **82**, 3697-
363 3701.

364 **Mathiason, C. K., Hays, S. A., Powers, J., Hayes-Klug, J., Langenberg, J.,**
365 **Dahmes, S. J., Osborn, D. A., Miller, K. V., Warren, R. J. & other authors**
366 **(2009).** Infectious prions in pre-clinical deer and transmission of chronic wasting
367 disease solely by environmental exposure. *PLoS One* **4**, e5916.

368 **Mathiason, C. K., Powers, J. G., Dahmes, S. J., Osborn, D. A., Miller, K. V.,**
369 **Warren, R. J., Mason, G. L., Hays, S. A., Hayes-Klug, J. & other authors (2006).**
370 Infectious Prions in the Saliva and Blood of Deer with Chronic Wasting Disease.
371 *Science* **314**, 133-136.

372 **Miller, M. W. & Williams, E. S. (2003).** Prion disease: horizontal prion transmission
373 in mule deer. *Nature* **425**, 35-36.

374 **Miller, M. W., Wild, M. A. & Williams, E. S. (1998).** Epidemiology of chronic
375 wasting disease in captive Rocky Mountain elk. *J Wildl Dis* **34**, 532-538.

376 **Plinston, C., Hart, P., Chong, A., Hunter, N., Foster, J., Piccardo, P., Manson, J.**
377 **C. & Barron, R. M. (2011).** Increased Susceptibility of Human-PrP Transgenic Mice
378 to Bovine Spongiform Encephalopathy Infection following Passage in Sheep. *J Virol*
379 **85**, 1174-1181.

380 **Race, B., Meade-White, K., Race, R. & Chesebro, B. (2009a).** Prion infectivity in
381 fat of deer with Chronic Wasting Disease. *J Virol* **1**, 1.

382 **Race, B., Meade-White, K. D., Miller, M. W., Barbian, K. D., Rubenstein, R.,**
383 **LaFauci, G., Cervenakova, L., Favara, C., Gardner, D. & other authors (2009b).**
384 Susceptibilities of nonhuman primates to chronic wasting disease. *Emerg Infect Dis*
385 **15**, 1366-1376.

386 **Race, B. L., Meade-White, K. D., Ward, A., Jewell, J., Miller, M. W., Williams,**
387 **E. S., Chesebro, B. & Race, R. E. (2007).** Levels of abnormal prion protein in deer
388 and elk with chronic wasting disease. *Emerg Infect Dis* **13**, 824-830.

389 **Sandberg, M. K., Al-Doujaily, H., Sigurdson, C. J., Glatzel, M., O'Malley, C.,**
390 **Powell, C., Asante, E. A., Linehan, J. M., Brandner, S. & other authors (2010).**
391 Chronic wasting disease prions are not transmissible to transgenic mice
392 overexpressing human prion protein. *J Gen Virol* **91**, 2651-2657.

393 **Sigurdson, C. J., Williams, E. S., Miller, M. W., Spraker, T. R., O'Rourke, K. I.**
394 **& Hoover, E. A. (1999).** Oral transmission and early lymphoid tropism of chronic
395 wasting disease PrPres in mule deer fawns (*Odocoileus hemionus*). *J Gen Virol* **80** (
396 **Pt 10**), 2757-2764.

397 **Spraker, T. R., Zink, R. R., Cummings, B. A., Wild, M. A., Miller, M. W. &**
398 **O'Rourke, K. I. (2002).** Comparison of histological lesions and

immunohistochemical staining of proteinase-resistant prion protein in a naturally occurring spongiform encephalopathy of free-ranging mule deer (*Odocoileus hemionus*) with those of chronic wasting disease of captive mule deer. *Vet Pathol* **39**, 110-119.

Stack, M. J., Focosi-Snyman, R., Cawthraw, S., Davis, L., Chaplin, M. J. & Burke, P. J. (2009). Third atypical BSE case in Great Britain with an H-type molecular profile. *Vet Rec* **165**, 605-606.

Tamguney, G., Giles, K., Bouzamondo-Bernstein, E., Bosque, P. J., Miller, M. W., Safar, J., DeArmond, S. J. & Prusiner, S. B. (2006). Transmission of elk and deer prions to transgenic mice. *J Virol* **80**, 9104-9114.

Trifilo, M. J., Ying, G., Teng, C. & Oldstone, M. B. (2007). Chronic wasting disease of deer and elk in transgenic mice: oral transmission and pathobiology. *Virology* **365**, 136-143.

Wilson, R., Hart, P., Piccardo, P., Hunter, N., Casalone, C., Baron, T. & Barron, R. (2012). Bovine PrP expression levels in Transgenic mice Influence Transmission Characteristics of Atypical BSE. *Journal of General Virology*.

Table 1. Transmission of BASE, BSE-H, CWD and atypical scrapie to human and bovine PrP Tg mice.

TSE Isolate	Mouse Line									
	HuMM		HuMV		HuVV		Bov6 [‡]		129/Ola [‡]	
	Survival Time	No. affected	Survival Time	No. affected	Survival Time	No. affected	Survival Time	No. affected	Survival Time	No. affected
BASE (Roslin)	>687	0/24	>672	0/24	>763	0/24	547±18*	24/24 [†]	>687	1/24 [†]
BASE (Milan)	>753	0/23	>700	0/23	>726	0/19	na	na	na	na
BASE# 1 (Rome)	>633	0/19	>680	0/14	>707	0/17	na	na	na	na
BASE#2 (Rome)	>604	0/16	>854	0/29	>740	0/20	na	na	na	na
BSE-C (Rome)	>592	0/14	>856	0/15	>509	0/13	na	na	na	na
BSE-H	>722	0/24	>708	0/24	>708	0/24	561±15*	17/23 [†]	675±19*	5/23 [†]
CWD	>680	0/24	>730	0/24	>722	0/24	>716	0/23	457,707	2/24 [†]
Sheep passaged atypical scrapie	>693	0/24	>693	0/24	>693	0/24	>693	0/24	>693	0/24
Atypical scrapie ARR/ARR1	>651	0/23	>724	0/21	>829	0/24	>781	0/24	>753	0/24
Atypical scrapie AHQ/AHQ1	>822	0/24	>718	0/24	>682	0/22	>757	0/23	>710	0/11
Atypical scrapie ARR/ARR2	>722	0/24	>744	0/24	>841	0/23	>756	0/22	>673	0/12
Atypical scrapie AHQ/AHQ2	>786	0/22	>768	0/23	>700	0/24	>805	0/24	>779	0/21
Atypical scrapie AFRQ/AFRQ1	>815	0/24	>717	0/23	>759	0/23	>757	0/23	>772	0/24

Atypical scrapie AFRQ/AFRQ2	>750	0/23	>722	0/23	>756	0/24	>726	0/24	>756	0/12
--------------------------------	------	------	------	------	------	------	------	------	------	------

>n Represents the survival in days of the oldest mouse in groups where pathological signs of disease were not observed in any animals.

* Measured as days \pm standard errors of the means and calculated from mice showing pathological signs of disease (vacuolation and/or PrP deposition)

† Number of mice showing pathological signs of disease (vacuolation and/or PrP deposition)/number of mice inoculated.

‡ Results for BASE and H-type BSE inoculations into Bov6 mice and 129/Ola mice have previously been published (Wilson *et al.*, 2012).

Table 2. Cases of clinically positive signs of disease in human and bovine PrP Tg mice inoculated with atypical scrapie

	HuMM		HuMV		HuVV		Bov6		129/Ola	
	Clin +ve	n	Clin +ve	n	Clin +ve	n	Clin +ve	n	Clin +ve	n
Atypical scrapie ARR/ARR-1	0	23	1	21	0	24	0	24	0	24
Atypical scrapie AHQ/AHQ-1	1	24	3	24	3	22	0	23	0	11
Atypical scrapie ARR/ARR-2	2	24	2	24	0	23	0	22	0	12
Atypical scrapie AHQ/AHQ-2	1	22	2	23	1	24	0	24	1	21
Atypical scrapie AFRQ/AFRQ-1	6	24	1	23	0	23	1	23	0	24
Atypical scrapie AFRQ/AFRQ-2	0	23	0	23	0	24	0	24	0	12
Total Clin+ve atypical scrapie cases	10	140	9	138	4	140	1	140	1	104